Itaru Mizoguchi

Itaru Mizoguchi

Auto-generated profile, based on publicly available information

Itaru Mizoguchi

Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, Sendai, Japan

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HKHideki Kitaura
Hideki Kitaura
AMAseel Marahleh
Aseel Marahleh
FOFumitoshi Ohori
Fumitoshi Ohori
TNTakahiro Noguchi
Takahiro Noguchi
WSWei-Ren Shen
Wei-Ren Shen
IMItaru Mizoguchi
Itaru Mizoguchi
The process of bone remodeling is the result of the regulated balance between bone cell populations, namely bone-forming osteoblasts, bone-resorbing osteoclasts, and the osteocyte, the mechanosensory cell type. Osteoclasts derived from the hematopoietic stem cell lineage are the principal cells involved in bone resorption. In osteolytic diseases such as rheumatoid arthritis, periodontitis, and osteoporosis, the balance is lost and changes in favor of bone resorption. Therefore, it is vital to elucidate the mechanisms of osteoclast formation and bone resorption. It has been reported that osteocytes express Receptor activator of nuclear factor κΒ ligand (RANKL), an essential factor for osteoclast formation. RANKL secreted by osteocytes is the most important factor for physiologically supported osteoclast formation in the developing skeleton and in pathological bone resorption such as experimental periodontal bone loss. TNF-α directly enhances RANKL expression in osteocytes and promotes osteoclast formation. Moreover, TNF-α enhances sclerostin expression in osteocytes, which also increases osteoclast formation. These findings suggest that osteocyte-related cytokines act directly to enhance osteoclast formation and bone resorption. In this review, we outline the most recent knowledge concerning bone resorption-related cytokines and discuss the osteocyte as the master regulator of bone resorption and effector in osteoclast formation.

Verified
Journal Article
Open access
PDF file
HKHideki Kitaura
Hideki Kitaura
AMAseel Marahleh
Aseel Marahleh
FOFumitoshi Ohori
Fumitoshi Ohori
TNTakahiro Noguchi
Takahiro Noguchi
YNyasuhiko nara
yasuhiko nara
IMItaru Mizoguchi
Itaru Mizoguchi
Tumor necrosis factor-α (TNF-α) is a pleiotropic cytokine expressed by macrophages, monocytes, and T cells, and its expression is triggered by the immune system in response to pathogens and their products, such as endotoxins. TNF-α plays an important role in host defense by inducing inflammatory reactions such as phagocytes and cytocidal systems activation. TNF-α also plays an important role in bone metabolism and is associated with inflammatory bone diseases. TNF-α binds to two cell surface receptors, the 55kDa TNF receptor-1 (TNFR1) and the 75kDa TNF receptor-2 (TNFR2). Bone is in a constant state of turnover; it is continuously degraded and built via the process of bone remodeling, which results from the regulated balance between bone-resorbing osteoclasts, bone-forming osteoblasts, and the mechanosensory cell type osteocytes. Precise interactions between these cells maintain skeletal homeostasis. Studies have shown that TNF-α affects bone-related cells via TNFRs. Signaling through either receptor results in different outcomes in different cell types as well as in the same cell type. This review summarizes and discusses current research on the TNF-α and TNFR interaction and its role in bone-related cells.

Verified
Journal Article
Open access
PDF file
FOFumitoshi Ohori
Fumitoshi Ohori
HKHideki Kitaura
Hideki Kitaura
SOSaika Ogawa
Saika Ogawa
WSWei-Ren Shen
Wei-Ren Shen
JQJiawei Qi
Jiawei Qi
IMItaru Mizoguchi
Itaru Mizoguchi
Interleukin (IL)-33 is a member of the IL-1 family, which acts as an alarmin. Several studies suggested that IL-33 inhibited osteoclastogenesis and bone resorption. Tumor necrosis factor-α (TNF-α) is considered a direct inducer of osteoclastogenesis. However, there has been no report regarding the effect of IL-33 on TNF-α-induced osteoclastogenesis and bone resorption. The objective of this study is to investigate the role of IL-33 on TNF-α-induced osteoclastogenesis and bone resorption. In an in vitro analysis of osteoclastogenesis, osteoclast precursors, which were derived from bone marrow cells, were treated with or without IL-33 in the presence of TNF-α. Tartrate-resistant acid phosphatase (TRAP) staining solution was used to assess osteoclast formation. In an in vivo analysis of mouse calvariae, TNF-α with or without IL-33 was subcutaneously administrated into the supracalvarial region of mice daily for 5 days. Histological sections were stained for TRAP, and osteoclast numbers were determined. Using micro-CT reconstruction images, the ratio of bone destruction area on the calvariae was evaluated. The number of TRAP-positive cells induced by TNF-α was significantly decreased with IL-33 in vitro and in vivo. Bone resorption was also reduced. IL-33 inhibited IκB phosphorylation and NF-κB nuclear translocation. These results suggest that IL-33 inhibited TNF-α-induced osteoclastogenesis and bone resorption.

Verified
Journal Article
Open access
PDF file
HKHideki Kitaura
Hideki Kitaura
SOSaika Ogawa
Saika Ogawa
FOFumitoshi Ohori
Fumitoshi Ohori
TNTakahiro Noguchi
Takahiro Noguchi
AMAseel Marahleh
Aseel Marahleh
IMItaru Mizoguchi
Itaru Mizoguchi
Patients with type 2 diabetes have an increased risk of fracture compared to the general population. Glucose absorption is accelerated by incretin hormones, which induce insulin secretion from the pancreas. The level of the incretin hormone, glucagon-like peptide-1 (GLP-1), shows an immediate postprandial increase, and the circulating level of intact GLP-1 is reduced rapidly by dipeptidyl peptidase-4 (DPP-4)-mediated inactivation. Therefore, GLP-1 receptor agonists and DPP-4 inhibitors are effective in the treatment of type 2 diabetes. However, these incretin-related diabetic agents have been reported to affect bone metabolism, including bone formation and resorption. These agents enhance the expression of bone markers, and have been applied to improve bone quality and bone density. In addition, they have been reported to suppress chronic inflammation and reduce the levels of inflammatory cytokine expression. Previously, we reported that these incretin-related agents inhibited both the expression of inflammatory cytokines and inflammation-induced bone resorption. This review presents an overview of current knowledge regarding the effects of incretin-related diabetes drugs on osteoblast differentiation and bone formation as well as osteoclast differentiation and bone resorption. The mechanisms by which incretin-related diabetes drugs regulate bone formation and bone resorption are also discussed.

1 October 2012 in European Journal of Orthodontics
Verified
Journal Article
Open access
PDF file
MIMasahiro Iijima
Masahiro Iijima
MTMasamitsu Takano
Masamitsu Takano
YYYoshitaka Yasuda
Yoshitaka Yasuda
TMTakeshi Muguruma
Takeshi Muguruma
SNSusumu Nakagaki
Susumu Nakagaki
IMItaru Mizoguchi
Itaru Mizoguchi
This study examined the influence of the quantity and quality of cortical bone on the failure force of miniscrew implants. Twenty-six titanium alloy miniscrew implants (AbsoAnchor) 1.4mm in diameter and 5 or 7mm long were placed in cross-sectioned maxillae (n = 6) and mandibles (n = 20) of human cadavers. Computed tomography imaging was used to estimate the cortical bone thickness and bone mineral density [total bone mineral density (TBMD, values obtained from cortical bone plus trabecular bone); cortical bone mineral density (CBMD, values obtained from only cortical bone)]. Maximum force at failure was measured in a shear test. Nanoindentation tests were performed to measure the hardness and elastic modulus of cortical bone around the miniscrew implants. The mean failure force of miniscrew implants placed in mandibles was significantly greater than that for implants in maxillae, and the bone hardness of mandibles was significantly greater than that of maxillae. The length of miniscrew implants did not influence the mean failure force in monocortical placement in the mandible. Cortical bone thickness, TBMD, CBMD, and bone hardness were significantly related to the mean failure force. CBMD was related to the mechanical properties of cortical bone. In conclusion, the quantity and quality of cortical bone greatly influenced the failure force of miniscrew implants.

24 March 2021 in Journal of Periodontal Research
Verified
Journal Article
Closed access
PDF file
HJHongtao Jiang
Hongtao Jiang
HKHideki Kitaura
Hideki Kitaura
LLLin Liu
Lin Liu
IMItaru Mizoguchi
Itaru Mizoguchi
SLShiying Liu
Shiying Liu